19 VESTRY STREET, NEW YORK, NY
Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
Management's Discussion and Analysis for the Third Quarter Ended June 30, 2025 (All Amounts Expressed in Canadian Dollars, Unless Otherwise Stated)
Management's Discussion and Analysis for the Second Quarter Ended March 31, 2025
To Present at the 2025 Jefferies Global Healthcare Conference
Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101
To Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
To Participate at Three Healthcare Conferences in March
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
No filings found
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report